OncoSec Medical Inc. (OTCQB: ONCS),
a company developing its ImmunoPulse DNA-based immunotherapy to treat
solid tumors, will present at the 13th Annual Needham
Healthcare Conference and the HemOnc Today Melanoma and Cutaneous
Malignancies Meeting in April.
Punit Dhillon, President and CEO, will present a corporate overview of
the company at the 13th Annual Needham Healthcare Conference
at the Westin Grand Central Hotel in New York City on Tuesday, April 8th,
at 11:20 a.m. ET. That presentation will be webcast live, and available
at the following link: http://wsw.com/webcast/needham65/oncs
OncoSec recommends registering at least 10 minutes prior to the start of
the presentation to ensure timely access. After the presentation, an
archived version of the webcast will be available for 90 days in the
“Events” section of the OncoSec web page at http://www.oncosec.com
Additionally, Adil Daud, M.D., Principal Investigator for OncoSec’s
Phase 2 melanoma study, will discuss developing intralesional therapies
at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the
Sheraton New York Times Square Hotel, in New York City on Friday, April
11th, at 2:40 p.m. ET.
HemOnc Today will bring together more than 25 renowned speakers and 200
colleagues to participate in an intimate and interactive meeting during
the weekend of April 11-12, 2014, in New York City, New York. The
dynamic meeting program is designed to encourage open communications and
exchange of ideas among leading hematologists, oncologists,
dermatologists, researchers, physician assistants, nurses, and students.
For more information, please visit: http://www.healio.com/meeting/hemonctodaymelanoma/home
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
ImmunoPulse immunotherapy to treat solid tumors. OncoSec’s core
technology leverages a proprietary electroporation platform to
enhance the local delivery and uptake of IL-12 and other DNA-based
immune-modulating agents. Clinical studies of ImmunoPulse have
demonstrated an acceptable safety profile and preliminary evidence of
anti-tumor activity in the treatment of various skin cancers, as well as
the potential to initiate a systemic immune response without the
systemic toxicities associated with other treatments. OncoSec’s clinical
programs currently include three Phase 2 trials in patients with
metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these indications,
it is also investigating additional indications and combination therapy
approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward-looking statements.” Forward-looking statements
are based on management’s current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical’s filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2014